2019
DOI: 10.1016/j.atherosclerosis.2019.02.001
|View full text |Cite
|
Sign up to set email alerts
|

Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
64
0
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 55 publications
(66 citation statements)
references
References 35 publications
1
64
0
1
Order By: Relevance
“…Anti-PCSK9 vaccines are a new generation of PCSK9 inhibitors, whose LDL-lowering effect is frequently verified in preclinical studies [27][28][29][30]. In a previous study, we reported a nanoliposomal anti-PCSK9 vaccine with long-lasting, specific and safe inhibitory effects on plasma PCSK9 in BALB/c mice [31].…”
Section: Introductionmentioning
confidence: 93%
See 1 more Smart Citation
“…Anti-PCSK9 vaccines are a new generation of PCSK9 inhibitors, whose LDL-lowering effect is frequently verified in preclinical studies [27][28][29][30]. In a previous study, we reported a nanoliposomal anti-PCSK9 vaccine with long-lasting, specific and safe inhibitory effects on plasma PCSK9 in BALB/c mice [31].…”
Section: Introductionmentioning
confidence: 93%
“…sized and high performance liquid chromatography (HPLC)-purified by ChinaPeptides Co., Ltd. (Shanghai, China). The already designed IFPT construct [31] contains a PCSK9 peptide, as a B cell epitope inspired from the AFFiRiS group [27,32], and a T-helper cell epitope belonging to tetanus toxin included as a standard adjuvant carrier [33] ( Table I). To link the IFPT epitope on the surface of liposome nanoparticles, it was bound to DSPE-PEG-Mal (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(PEG)-2000]) lipid (Lipoid GmbH, Germany) via an N-terminal cysteine residue inserted in IFPT peptide ( Figure 1).…”
Section: Preparation and Characterization Of The Liposome Nanoparticlesmentioning
confidence: 99%
“…Our recent study has shown that the nanoliposomal antiPCSK9 vaccine can directly target and inhibit circulating PCSK9 and efficiently decrease elevated levels of plasma LDL-C in mice [38]. Inconsistent associations between circulating lipids and risk of breast cancer have been reported by observational and Mendelian randomization studies [9][10][11][12][13][14][15][16].…”
Section: Discussionmentioning
confidence: 99%
“…The Immunogenic Fused PCSK9-Tetanus (IFPT) peptide was synthesized and purified by high performance liquid chromatography (HPLC) to a purity > 95% by ChinaPeptides Co., Ltd. (Shanghai, China). The previously designed IFPT construct [38] contains a PCSK9 peptide, as a B cell epitope inspired from the AFFiRiS group [35,39], and a T-helper cell epitope belonging to the tetanus toxin used as a pharmaceutically acceptable carrier [40] (Table I). To attach the IFPT epitope on the surface of liposome nanoparticles, it was linked to DSPE-PEG-Mal (1,2-distearoyl-sn-glycero-3-phos phoethanolamine-N-[maleimide(PEG)-2000]) lipid (Lipoid GmbH, Germany) via an N-terminal cysteine residue added to IFPT peptide (Supplementary Figure S1).…”
Section: Immunogenic Peptidementioning
confidence: 99%
See 1 more Smart Citation